Vertex Pharmaceuticals Incorporated (ETR:VX1)
352.85
-6.20 (-1.73%)
Oct 10, 2025, 5:35 PM CET
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B USD in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.39B, up 10.16% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.39B
Revenue Growth
+10.16%
P/S Ratio
9.25
Revenue / Employee
$1.87M
Employees
6,100
Market Cap
89.95B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
Dec 31, 2018 | 3.05B | 558.95M | 22.46% |
Dec 31, 2017 | 2.49B | 786.48M | 46.20% |
Dec 31, 2016 | 1.70B | 669.84M | 64.89% |
Dec 31, 2015 | 1.03B | 451.92M | 77.86% |
Dec 31, 2014 | 580.42M | -631.56M | -52.11% |
Dec 31, 2013 | 1.21B | -315.07M | -20.63% |
Dec 31, 2012 | 1.53B | 116.42M | 8.25% |
Dec 31, 2011 | 1.41B | 1.27B | 883.91% |
Dec 31, 2010 | 143.37M | 41.48M | 40.71% |
Dec 31, 2009 | 101.89M | -73.62M | -41.94% |
Dec 31, 2008 | 175.50M | -23.51M | -11.81% |
Dec 31, 2007 | 199.01M | -17.34M | -8.02% |
Dec 31, 2006 | 216.36M | 55.47M | 34.47% |
Dec 31, 2005 | 160.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Vertex Pharmaceuticals News
- 1 day ago - Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News - GuruFocus
- 3 days ago - VRTX: JP Morgan Raises Price Target to $530 | VRTX Stock News - GuruFocus
- 3 days ago - Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity - Benzinga
- 3 days ago - Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Nasdaq
- 5 days ago - Vertex to Announce Third Quarter 2025 Financial Results on November 3rd - Business Wire
- 5 days ago - Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga
- 5 days ago - Noteworthy ETF Outflows: VUG, SYK, BX, VRTX - Nasdaq
- 8 days ago - Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus